Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy
BRCA2-loss CAPC displays a distinct genomic landscape, marked by robust HRD features, suggesting the potential of higher sensitivity to PARPi. These findings highlight the relevance of HRDsig, and routinely use of CGP in refining patient selection for PARPi and guiding the design of future clinical trials.
Authors
- Gennady Bratslavsky (ORCID: https://orcid.org/0000-0002-2712-4375)
- Valentina Tateo (ORCID: https://orcid.org/0000-0002-1199-2338)
- Alina Basnet (ORCID: https://orcid.org/0000-0002-6033-6943)
- A. M. Kamat
- Antonio Cigliola (ORCID: https://orcid.org/0009-0005-7109-2429)
- Michela Piacentini
- Jeffrey A. Ross (ORCID: https://orcid.org/0000-0002-7002-4548)
- P. Grivas
- J L Lortat Jacob
- Andrea Necchi
- Philippe E Spiess
- Neeraj Agarwal
- Dean Pavlick
- Chiara Mercinelli
- Brigida Anna Maiorano
- Roger Li
- Shilpa Gupta
Institutions
- University of Verona (IT)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- SUNY Upstate Medical University (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- Fred Hutch Cancer Center (US)
- Mylan (South Africa) (ZA)
- PHG Foundation (GB)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-03-20
- DOI
- https://doi.org/10.1093/oncolo/oyag100
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00